Effect of Caffeine-Containing Beverages on Physicochemical and Release Properties of Halofantrine
Keywords:
caffeine, halofantrine, physicochemical interaction
Abstract
Halofantrine (Hf) is a poorly water-soluble drug for treating malaria in endemic areas like tropical Africa, where caffeine-containing products are habitually consumed. Previous reports showed that caffeine increased the aqueous solubility of Hf at room temperature over 3 days. The aim of this study was to determine the effect of caffeine and caffeine-containing beverages on dissolution and solubility of Hf and to investigate any possible interactions. The aqueous solubility and dissolution of Hf alone and in the presence of caffeine was investigated at pH 1.3, 5.9 and 7.4 using standard methods. The solubility of Hf in the presence of aqueous extracts of cocoa, coffee, black tea and green tea at pH 5.9 was also investigated. In 1 hour, caffeine markedly increased the aqueous solubility of Hf at pH 1.3, 5.9 and 7.4. Caffeine and caffeine-containing beverages markedly increased the aqueous solubility of Hf by between 100-to more than 1600-fold, with a 1672-fold increase by caffeine (from 76.6 ±7.8 ng/mL to128.2 ± 4.5 mg/mL) at pH 5.9. The dissolution of Hf tablets at pH 1.3, 5.9 and 7.4 showed the respective amounts released as 3.57 ± 0.09, 0.95 ± 0.19 and 0.260 ± 0.043 mg, but introduction of caffeine increased these values to 9.51 ± 0.23, 3.70 ± 0.12 and 0.52 ± 0.10 mg respectively, representing 3-fold, 4-fold and 2-fold respectively.
Downloads
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
How to Cite
References
C. Babalola, A. Adegoke, M. Ogunjimi, M. Osimosu (2003) Determination of physicochemical properties of halofantrine Afr J Med Med Sci. 32(4), 357-359.
L. Schmidt, Ruth Crosby, Jane Rasco, Dennis Vaughan (1978) Antimalarial activities of various 9- phenanthrenemethanols with special attention to WR-122,455 and WR-171,669 Antimicrob Agents Chemother. 14(3), 292-314. https://doi.org/10.1128/aac.14.3.292
G. Childs, C. Lambros, J. Notsch, C. Pamplin, D. Davidson, A. Ager (1984) Comparison ofin vitroandin vivoantimalarial activities of g-phenanthrenecarbinols. 78(1), 13-20.
W. Watkins, J. Lury, D. Kariuki, D. Koech, J. Oloo, M. Mosoba, M. Mjomba, H. Gilles (1988) Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya Lancet. 2(8605), 247-250.
F. ter Kuile, F. Nosten, T. Chongsuphajaisiddhi, N. White, G. Dolan, C. Luxemburger, L. Phaipun, M. Edstein, H. Webster (1993) Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria Lancet. 341(8852), 1044-1049.
E. Boudreau, L. Pang, K. Dixon, H. Webster, K. Pavanand, L. Tosingha, P. Somutsakorn, C. Canfield (1988) Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand Bull World Health Organ. 66(2), 227-235.
Bryson HM, Goa KL (1992) Halofantrine A review of its antimalarial activity, pharmacokinetic properties and therapeutic potential Drugs. 43(2), 236-258.
K. Milton, G. Edwards, S. Ward, M. Orme, A. Breckenridge (1989) Pharmacokinetics of halofantrine in man: effects of food and dose size Br J Clin Pharmacol. 28(1), 71-77.
Sylvester Aideloje, Cyprian Onyeji, Nicholas Ugwu (1998) Altered Altered pharmacokinetics of halofantrine by an antacid, magnesium carbonate Eur J Pharm Biopharm. 46(3), 299-303. https://doi.org/10.1016/s0939-6411(98)00029-0
Bassi PU, Onyeji CO, Ukponmwan OE (2004) Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers Br J Clin Pharmacol. 58(1), 52-55.
Lee-Yong Lim, Mei-Lin Go (2000) Caffeine and nicotinamide enhances the aqueous solubility of the antimalarial agent halofantrine Eur J Pharm Sci. 10(1), 17-28. https://doi.org/10.1016/s0928-0987(99)00084-6
Yetunde Kolade, Chinedum Babalola, Ajibola Olaniyi, Gerhard Scriba (2008) Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine Eur J Clin Pharmacol. 64(1), 77-81. https://doi.org/10.1007/s00228-007-0387-0
Kolade YT, Babalola CP, Scriba GK (2006) Analysis of the antimalarial drug halofantrine and its major metabolite N-desbutylhalofantrine in human plasma by high performance liquid chromatography. 41(1), 315-9.
T. Tanaka, A. Okayama, S. Seguchi, M. Ohhashi, S. Tahara, M. Tamaki (2000) Contents of caffeine, theobromine and theophylline in favorite foods Nara Prefect Inst Public Health, Nara, Japan. 34, 71-73.
Cosgriff TM, Boudreau EF, Pamplin CL, Doberstyn EB, Desjardins RE, Canfield CJ (1982) Evaluation of the antimalarial activity of the phenanthrenemethanol halofantrine (WR 171,669). 31(6), 1075-9.
W. Colwell, V. Brown, P. Christie, J. Lange, C. Reece, K. Yamamoto, D. Henry (1972) Antimalarial arylaminopropanols. 15(7), 771-5.
E. Monlun, O. Pillet, J. Cochard, Favarel Garrigues, J., Le Bras, M. (1993) Prolonged QT interval with halofantrine. 341(8859), 1541-1542.
M. Fawzi, E. Davison, M. Tute (1980) Rationalization of drug complexation in aqueous solution by use of Hückel frontier molecular orbitals. 69(1), 104-6.
Rasool AA, Hussain AA, Dittert LW (1991) Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and related compounds. 80(4), 387-93.
S. Carter (1972) Carter SJ, Cooper and Gunn's Dispensing for Pharmaceutical Students. 10.
Published
2014-01-27
Issue
Section
License
Copyright (c) 2014 Authors and Global Journals Private Limited

This work is licensed under a Creative Commons Attribution 4.0 International License.